Clinical-epidemiological characterization of UNA cohort of patients with rheumatoid arthritis: Preliminary data
Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic inflammatory disease. Early diagnosis, the implementation of targeted, strict treatment goals and the development of new therapies, have improved the prognosis of these patients.
Objective: To provide detailed information on the demographic, clinical, and therapeutic characteristics of RA patients in the country.
Materials and Methods: Descriptive, cross-sectional study of a cohort of RA
patients from three tertiary centers. Clinical-epidemiological variables, disease activity, treatment, presence of radiological erosions, and degree of disability were analyzed. Qualitative variables were expressed as frequencies and percentages, and quantitative variables as means with standard deviation.
Results: The study included 426 patients with a diagnosis of RA, 84.5% female, with an average age of 56.8 ± 14.09 years, and a disease duration of 12.7±19.6 years. A total of 53.3% had a basic school education. 25.5% had extra-articular manifestations. 71.4% had positive anti-CCP and 69.2% had positive Rheumatoid Factor. 68.2% received methotrexate, and 39% were in disease remission by DAS 28. More than 60% had at least one comor- bidity, with high blood pressure and obesity being the most frequent.
Conclusion: We present the preliminary phase of a multicenter cohort of patients with RA that reveals the reality of Paraguayan patients. In this cohort of patients with already established RA, there is a predominance of women. The clinical characteristics showed a predominance of poor prognostic factors. The most frequent form of onset was polyarticular, the vast majority were seropositive and had high titers. One third of the patients presented extra-articular manifestations, the most frequent being dry eye. More than 60% had at least one comorbidity, the most frequent being hypertension and obesity.
Downloads
References
(1) Pavlov-Dolijanovic S, Bogojevic M, Nozica-Radulovic T, Radunovic G, Mujovic N. Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options. Med. 2023;59(10):1–21.
(2) Gravallese EM, Firestein GS. Rheumatoid Arthritis — Common Origins, Divergent Mechanisms. N Engl J Med. 2023;388(6):529–42.
(3) Salazar-Mejía CE, Galarza-Delgado DÁ, Colunga-Pedraza IJ, Azpiri- López JR, Wah-Suárez M, Wimer-Castillo BO, et al. Relationship Between Work Productivity and Clinical Characteristics in Rheumatoid Arthritis. Reumatol Clin. 2019;15(6):327–32.
(4) Barrera Castro SM, Suárez Moya ÁMG, Mora LM, Cardona C, Jáuregui Cuartas EA, Muñoz Urrego YA. Aproximación de discapacidad en artritis reumatoide. Resultados de un programa de atención integral. Rev Colomb Reumatol [Internet]. 2017;24(3): 138–44. Available from: https://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-articulo-aproximacion-discapacidad-artritis-reumatoide-resultados-S0121812317300294
(5) Ballina García FJ, Rodríguez Pérez A. Artritis reumatoide. Rev Española Reumatol [Internet]. 2000;27(6):256–9. Available from: https://www.elsevier.es/es-revista-revista-espanola-reumatologia-29-articulo-artritis-reumatoide-11714
(6) Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G, et al. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. Front Immunol. 2022;13:1051082.
(7) Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3–18.
(8) Wu C-Y, Yang H-Y, Luo S-F, Lai J-H. From Rheumatoid Factor to Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies for Diagnosis and Prognosis Prediction in Patients with Rheumatoid Arthritis. Int J Mol Sci. 2021 Jan;22(2).
(9) Acosta-Mérida Á, Naranjo A, Rodríguez-Lozano C. Prognostic Factors for Sustained Remission in a “Real Life” Cohort of Rheumatoid Arthritis Patients. Reumatol Clínica [Internet]. 2020;16(5):405–9. Available from: https://www.reumatologiaclinica.org/es-prognostic-factors-for-sustained-remission-articulo-S1699258X18302316
(10) Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017 Jun;76(6):948–59.
(11) Smith MH, Berman JR. What Is Rheumatoid Arthritis? Vol. 327, JAMA. United States; 2022. p. 1194.
(12) Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 Rheumatoidarthritisclassificationcriteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum [Internet]. 2010;62(9): 2569–81. Available from: https://doi.org/10.1002/art.27584
(13) Pisaniello HL, Whittle SL, Lester S, Menz F, Metcalf R, McWilliams L, et al. Using the derived 28-joint disease activity score patient- reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis. BMC Rheumatol. 2022 Nov;6(1):67.
(14) Miguel-Lavariega D, Elizararrás-Rivas J, Villarreal-Ríos E, Baltiérrez- Hoyos R, Velasco-Tobón U, Vargas-Daza ER, et al. [Epidemiological profile of rheumatoid arthritis]. Rev Med Inst Mex Seguro Soc [Inter- net]. 2023;61(5):574–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37757464%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC10599789
(15) Alcaide L, Torralba AI, Eusamio Serre J, García Cotarelo C, Loza E, Sivera F. Estado, control, impacto y manejo actual de la artritis reumatoide según los pacientes: encuesta nacional AR 2020. Reumatol Clínica. 2022;18(3):177–83.
(16) Martínez Téllez G, Torres Rives B, Gómez Morejón JA, Pérez Garay H, Rodríguez AM, Portal Miranda JÁ. Diagnostic Value of Anti-Fibrinogen Citrullinated Peptide in Rheumatoid Arthritis. Reumatol Clin. 2020;16(6):455–61.
(17) Calvo-Alén J, Corrales A, Sánchez-Andrada S, Fernández- Echevarría MA, Peña JL, Rodríguez-Valverde V. Outcome of late-onset rheumatoid arthritis. Clin Rheumatol. 2005 Sep;24(5): 485–9.
(18) Valinotti V, Román L, Paats A, Glizt R, Mallorquín A, Ávila-Pedretti G, et al. Relationship between disease duration and clinical features in patients with Rheumatoid Arthritis in two reference centers. Rev Paraguaya Reumatol. 2020;6(1):11–6.
(19) Muñetón López GA, Quintana L. G. El nivel educativo y su papel en enfermedades reumáticas. Rev Colomb Reumatol. 2014;21(4): 165–8.
(20) Bergström U, Jacobsson LTH, Nilsson J-Å, Wirfält E, Turesson C. Smoking, low formal level of education, alcohol consumption, and the risk of rheumatoid arthritis. Scand J Rheumatol [Internet]. 2013 Mar 1;42(2):123–30. Available from: https://doi.org/10.3109/03009742.2012.723744
(21) Capote AC, Estévez M, Kokuina E. Manifestaciones extrarticulares y anticuerpos contra péptidos cíclicos citrulinados en artritis reumatoide Extrarticular manifestations and antibodies against citrullinated cyclic peptides in rheumatoid arthritis. 2021;2021(4): 1–13.
(22) Morsley K, Miller A, Luqmani R, Fina-Aviles F, Javaid MK, Edwards CJ, et al. Rheumatoid factor testing in Spanish primary care: A population-based cohort study including 4.8 million subjects and almost half a million measurements. Reumatol Clin. 2019;15(6): 350–4.
(23) INE. Proyecciones de población nacional, áreas urbana y rural, por sexo y edad, 2021. Inst Nac Estad [Internet]. 2021;1–2. Available from: https://www.ine.gov.py/Publicaciones/Biblioteca/documento/7eb5_Paraguay_2021.pdf
(24) Rojas E, Cabrera-Villalba S. Rheumatoid Arthritis and Pregnancy. Upgrade. Rev Paraguaya Reumatol. 2020;6(1):36–47.
(25) Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study. Reumatol Clin. 2019;15(2):102–8.
(26) Rodríguez-Mejías MD, Rodríguez.Guzmán JA, Fuentes-Silva YJ. Associated comorbidities of patients with Rheumatoid Arthritis in external consultation. Rev Paraguaya Reumatol. 2022;8(1):34–40.
(27) Coussette UM, Biosca MEA. Rheumatoid factor with atherogenic risk markers in rheumatoid arthritis patients. Rev Cuba Investig Biomed. 2015;34(1):33–43.
(28) Díaz Cuña C, Consani S, Rostan S, Fernández L, Moreira E, Sanmartí R. Rheumatoid arthritis: Extra articular manifestations and comorbidities. Rev Colomb Reumatol. 2022;29(3):196–204.
(29) Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, et al. Survival in rheumatoid arthritis: a populationbased analysis of trends over 40 years. Arthritis Rheum. 2003 Jan;48(1):54–8.
(30) Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003 Aug;62(8):722–7.
Copyright (c) 2024 Sonia Cabrera Villalba, Claudia Coronel, Lourdes Román, Vannia Valinotti, Angélica Amarilla, Mariela Zarza, Evelyn Leiva, Paola Pusineri, Raquel Aranda, Alexis Pineda, Gabriela Avila Pedretti, Paloma de Abreu
This work is licensed under a Creative Commons Attribution 4.0 International License.
